clinical trial · NCT05936489
Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
Eye DiseasesPresbyopiaRefractive ErrorsBrimonidine TartrateAceclidineOphthalmic SolutionsAceclidine + BrimonidineAceclidine
brief summary
This is a single-center, open-label, randomized study to assess the plasma pharmacokinetic profile of LNZ101 and LNZ100.
started
Jul 6, 2023
primary completion
Oct 3, 2023
completion
Oct 3, 2023
last updated
Oct 16, 2023
detailed description
To characterize the plasma pharmacokinetics and safety profile of LNZ101 and LNZ100 ophthalmic solutions in both eyes once a day for 8 days in healthy volunteers with presbyopia
official title
A Prospective, Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety Following Topical Administration of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol